REVIEW article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1674079
This article is part of the Research TopicResearch and Innovation Approaches to Personalized Pharmacotherapies for Respiratory DiseasesView all 8 articles
Medicinal plants and compounds for chronic bronchitis treatment: efficacy and action mechanisms
Provisionally accepted- 1Beijing University of Chinese Medicine, Beijing, China
- 21st Medical Center of Chinese PLA General Hospital, Beijing, China
- 3China Academy of Chinese Medical Sciences Institute of Basic Theory of Traditional Chinese Medicine, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Chronic bronchitis (CB) is a common yet heterogeneous condition characterized by persistent inflammation, oxidative stress, airway hyperresponsiveness, and mucus hypersecretion. As an early stage of various severe pulmonary diseases, current therapeutic strategies remain unsatisfactory. Substantial evidence indicates that medicinal plants and compounds hold potential for treating inflammatory lung disorders. This study aims to consolidate recent and reliable evidence concerning the multi-targeted roles and underlying molecular mechanisms of these natural products in the treatment of CB. Methods: This systematic review followed a prospectively registered protocol (PROSPERO ID: CRD42024588912). A comprehensive literature search encompassed multiple electronic databases, including PubMed, Scopus, Embase, Web of Science, VIP, Wan-fang, SinoMed, and the China National Knowledge Infrastructure (CNKI). Study selection strictly adhered to the PICOS principles to systematically identify medicinal plants and compounds with therapeutic potential against CB. Results: The results identified 13 medicinal plants and 19 compounds that exhibited anti-inflammatory activity. Additionally, 8 plants and 12 compounds demonstrated further therapeutic effects, including antioxidant, anti-mucus, and potential bronchodilatory activities. The underlying mechanisms primarily involved the NF-κB, PI3K/AKT/mTOR, TLR4, MAPK, and Nrf2 pathways. Ursolic acid emerged as the most promising clinical candidate. Conclusion: This review represents the first comprehensive synthesis of experimentally verified efficacy and mechanisms associated with medicinal plants and compounds in CB treatment. Preclinical animal studies have confirmed the therapeutic benefits of these natural agents in alleviating CB symptoms, establishing a solid foundation for novel drug development and underscoring their considerable translational potential.
Keywords: Chronic bronchitis (CB), Chronic obstructive pulmonary disease (COPD), Phytotherapy, natural compounds, medicinal plants
Received: 27 Jul 2025; Accepted: 15 Oct 2025.
Copyright: © 2025 Ding, Chen, Li, Wang, Chen, Xu, Yang, Liu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhen Yang, for3000yz@aliyun.com
Zhenhong Liu, lzhh0399@163.com
Hongxia Zhao, zhaohongxia7000@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.